← Guides

How should nonconforming product and MRB dispositions be handled under ISO 13485 clause 8.3?

By Savi C., Co-Founder · Published Nov 16, 2026

What clause 8.3 requires

Clause 8.3.1 requires a documented procedure defining the controls, responsibilities and authorities for the identification, documentation, segregation, evaluation and disposition of nonconforming product. The evaluation has to include whether an investigation is needed and whether any external party responsible for the nonconformity, such as a supplier, must be notified. Records of the nature of the nonconformity and the actions taken, including the rationale for decisions, must be kept.

Neither ISO 13485 nor the QMSR uses the term material review board. An MRB is simply the way many manufacturers assign the authority clause 8.3.1 requires. What matters to an auditor is that the procedure names who can make each disposition and that the record shows the decision was made by someone with that authority.

Under the QMSR, the standard applies as incorporated, with FDA definitions on top. 21 CFR 820.3 defines rework as action taken on a nonconforming product so that it will fulfill the specified requirements in the medical device file before it is released for distribution.

Dispositions and what each needs on record

Disposition

Rework (8.3.4)

What the record has to show

Done to a documented procedure that considers the potential adverse effect of rework, approved the same way as the original procedure; product re-verified against applicable acceptance criteria and regulatory requirements; rework records kept

Disposition

Use as is or release under concession (8.3.2 c)

What the record has to show

Justification, approval, confirmation that applicable regulatory requirements are met, and the identity of the person authorizing the concession

Disposition

Scrap or other action precluding intended use (8.3.2 b)

What the record has to show

The product was physically prevented from reaching its original use, for example destroyed or segregated and relabeled for non-clinical use

Disposition

Return to supplier

What the record has to show

Evaluation of whether the supplier must be notified, and the input to supplier monitoring under clause 7.4.1

Disposition

Detected after delivery (8.3.3)

What the record has to show

Action appropriate to the effects or potential effects of the nonconformity, records of that action, and advisory notices handled under the documented procedure and, in the US, Part 806 as 820.10(b)(4) requires

Reviewing a nonconformance record before closure

Identification and control

  • Affected quantity and lot or serial numbers identified, and all of it located and segregated
  • Nature of the nonconformity described against the specific requirement it fails
  • Decision on whether an investigation is needed, with the rationale written down
  • Decision on whether a supplier or other external party must be notified

Disposition

  • Disposition made by a person or board the procedure authorizes for that disposition
  • For a concession: justification, approval and regulatory requirements check all present
  • For rework: the procedure used was approved, and its revision is cited
  • For rework: re-verification results present for the criteria the rework could have affected
  • For scrap: evidence of destruction or segregation, with quantities reconciled

Closure

  • The record for each affected device or batch references the nonconformance and its disposition
  • Release of affected product only after the disposition was recorded
  • Need for corrective action assessed and, where raised, the CAPA number linked

Where MRB records tend to fail

The weak points are usually the concession and the rework. A use-as-is decision signed without a written justification, or justified by "no impact" with no reasoning, does not meet the clause 8.3.2 condition. Reworked product released on the strength of the original inspection, without re-verification, does not meet clause 8.3.4. And a disposition recorded in the nonconformance system but not referenced in the device or batch record leaves the release reviewer unable to see it. For how nonconformances feed corrective action, see the guide How do you check CAPA effectiveness?

How Litewave fits

Litewave reads paper or electronic records, checks every entry against your master record and specifications, and shows QA only the exceptions, each linked to the page it came from. In a device record that includes flagging an out-of-specification result with no linked nonconformance, or a nonconformance with no disposition. Litewave proposes, qualified people approve, and it never makes a disposition on its own. Our published results come from pharmaceutical manufacturing, and device figures will be published only when a device customer has agreed to them.

Questions we get asked

Does ISO 13485 require a material review board?

No. It requires documented controls, responsibilities and authorities for disposition. An MRB is one common way to assign that authority, often for concessions, but a procedure can name individual roles instead.

Can a use-as-is decision be made without the customer?

Clause 8.3.2 requires justification, approval and that applicable regulatory requirements are met. Whose approval is needed depends on your procedures and agreements: a contract manufacturer will usually need its customer to approve a concession under the quality agreement.

Does reworked product need full re-testing?

Clause 8.3.4 requires reworked product to be verified to ensure it meets applicable acceptance criteria and regulatory requirements. The rework procedure should define which criteria the rework could affect and therefore must be re-verified, and should be approved the same way as the original procedure.

Sources

  1. ISO 13485:2016, Medical devices, Quality management systems
  2. 21 CFR 820.3, Definitions (eCFR)
  3. 21 CFR 820.10, Requirements for a quality management system (eCFR)
  4. 21 CFR Part 806, Corrections and removals (eCFR)
  5. Advisera 13485 Academy, Nonconforming product: how to approach the post-delivery actions